Dizal Pharmaceuticals

This early-stage study tests an experimental drug called DZD6008 in people with advanced non-small cell lung cancer that has specific EGFR gene mutations. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 140 adults whose c…

This study tests an experimental drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This study tests a combination of two experimental drugs, DZD9008 and AZD4205, in people with advanced non-small cell lung cancer that has EGFR mutations and has stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About …

This study tests a new combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma, a type of blood cancer. The first part finds the safest dose, and the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed disease…

This early-stage study tests a new drug, DZD6008, in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety and find the right dose. About 190 adults will take part, and researchers will also watch for any …

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. About 218 participants will be randomly assigned to receive either golidocitinib or a…

This study tests a new drug called DZD8586 combined with other treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults with either untreated or relapsed/refractory DLBCL will receive the combination therapy. Researchers will measure how…

This study tests an experimental drug called DZD8586 in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed at least one standard treatment and have low platelet counts. T…

This study tests an experimental drug called DZD8586 in adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to prior treatments. The goal is to see how well the drug controls the cancer and what side effects it may cause. Abo…